Mitchell Levine's most recent trade in Insight Molecular Diagnostics Inc. was a trade of 87,500 Option to Purchase Common Stock done . Disclosure was reported to the exchange on March 15, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 87,500 | 87,500 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 87,500 | 87,500 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.17 per share. | 15 Mar 2022 | 25,000 | 87,080 (0%) | 0% | 1.2 | 29,150 | Common Stock, no par value |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2021 | 20,000 | 0 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2021 | 20,000 | 66,700 (0%) | 0% | 0 | Common Shares, no par value | |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 28 Apr 2021 | 4,620 | 62,080 (0%) | 0% | 0 | Common Shares, no par value | |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 255,000 | 255,000 | - | - | Employee Stock Option (right to buy) | |
| Insight Molecular Diagnost... | Mitchell Levine | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 10,121 | 46,700 (0%) | 0% | - | Common Stock | |
| Insight Molecular Diagnost... | Mitchell Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.32 per share. | 03 Aug 2020 | 10,000 | 36,579 (0%) | 0% | 1.3 | 13,200 | Common Stock, no par value |